Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...
TT125-802 targets transcriptional pathways in NSCLC with EGFR or KRAS-G12C mutations, addressing resistance to current therapies. The therapy has shown promising single-agent activity and a favorable ...
Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...
Erasca (NASDAQ:ERAS) executives outlined the company’s strategy to target RAS-driven cancers and previewed upcoming clinical milestones during a fireside chat hosted by Oppenheimer oncology analyst ...
APC, adenomatous polyposis coli; CBP, cAMP-response element binding protein; CIBP, calcium- and integrin-binding protein; CK, creatine kinase. CtBP, C-terminal binding protein; GRO, growth-regulated ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Many cases are driven by mutations in the EGFR gene, which causes cells to grow and divide uncontrollably. In Southeast Asia, these mutations are found in up to 40–60% of a common type of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results